Premium
A study of clinico‐pathological parameters and O 6 – methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma
Author(s) -
Singh Geetika,
Mallick Supriyo,
Sharma Vikas,
Joshi Nikhil,
Purkait Suvendu,
Jha Prerana,
Sharma Mehar Chand,
Suri Vaishali,
Julka Pramod Kumar,
Mahapatra Ashok Kumar,
Singh Manmohan,
Kale Shashank Sharad,
Sarkar Chitra
Publication year - 2012
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/j.1440-1789.2012.01297.x
Subject(s) - gliosarcoma , o 6 methylguanine dna methyltransferase , methylation , methyltransferase , dna methylation , pathological , cancer research , dna , medicine , biology , glioblastoma , pathology , genetics , gene , gene expression
Gliosarcoma is a rare variant of glioblastoma multiforme (GBM) with similar clinical presentation and prognosis but a distinct genetic profile. The clinicopathological features of 22 cases of gliosarcoma were analyzed with respect to age, sex, KPS score, operative diagnosis, extent of resection and histopathological subtype (predominantly sarcomatous [PS], predominantly gliomatous [PG] or mixed). Twelve cases were PS, six were PG and four were mixed. The histological subtype did not correlate with the operative diagnosis; however, it did significantly correlate with the extent of resection ( P = 0.014). In 14 cases with available survival data it was found that none of the clinicopathological parameters significantly correlated with survival ( P > 0.05). Methyl guanine DNA methyl transferase promoter methylation studies were performed using methylation‐specific PCR in 16 cases which showed a methylation rate of 31.25% (5/16). The promoter methylation status did not correlate with the histological subtype and did not significantly affect survival ( P > 0.05). Although gliosarcomas continue to be treated in the same way as GBM, the role of chemotherapy with temozolomide is not clear. This cohort is the largest to date to uniformly receive the Stupp's protocol which is currently “standard of care” for GBM. A median overall survival of 18.5 months is substantially higher than previous studies, suggesting that temozolomide should be included in gliosarcoma therapy.